ArriVent BioPharma Announces Presentation of Key Preclinical Data at AACR 2026 Annual Meeting

NEWTOWN SQUARE, PA, March 17, 2026 – ArriVent BioPharma, Inc. (Nasdaq: AVBP), a clinical-stage biopharmaceutical company focused on developing innovative cancer therapeutics, announced two pivotal preclinical poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, from April 17-22, 2026.

Key Highlights from the Announcement

• Firmonertinib: Unique structural features and preclinical data support its ongoing global Phase 3 studies in EGFR mutant non-small cell lung cancer (NSCLC), including challenging exon 20 insertion mutations.
• ARR-002 (AV-P138-ADC): A novel dual-target MUC16/NaPi2b tetravalent antibody drug conjugate (ADC) demonstrating superior anti-tumor activity in ovarian and endometrial cancer models, with a favorable tolerability profile.
• Potential Price-Sensitive Developments: Both assets are advancing towards late-stage clinical development and may address major unmet needs in cancer therapy, which could have significant implications for ArriVent’s future valuation and competitive position.

Details of Firmonertinib Preclinical Presentation

• Abstract Title: Discovery and Characterization of Firmonertinib, a Novel EGFR Inhibitor with Broad Activity Against both EGFR Classical and Exon 20 Insertion Mutations
• Presentation Details: April 21, 2026, 2:00–5:00 PM PT, Experimental and Molecular Therapeutics / Tyrosine Kinase, Phosphatase & Other Inhibitors, Section 18, Board 9, Number 5871
• Preclinical Results:
  • Firmonertinib is a brain-penetrant, irreversible EGFR inhibitor with demonstrated high potency against both classical and exon 20 insertion mutations.
  • Early clinical evidence suggests efficacy against uncommon EGFR mutations, including ex20ins and PACC variants.
  • Already approved in China for frontline classical and second-line exon20ins EGFR mutant NSCLC.
  • Structural, biochemical, cell line, and xenograft studies confirmed:
    • High potency inhibition across EGFR mutations.
    • Strong anti-tumor activity and high brain penetrance in multiple in vitro and in vivo models.
    • Supports the broad EGFR binding and inhibition mechanism.

Details of ARR-002 (AV-P138-ADC) Preclinical Presentation

• Abstract Title: AV-P138-ADC (ARR-002), a Novel MUC16/NaPi2b Dual-target Tetravalent ADC, for the Treatment of Ovarian and Endometrial Cancers
• Presentation Details: April 20, 2026, 9:00 AM–12:00 PM PT, Clinical Research / Targeted Antigen Therapies and Immunity, Section 49, Board 12, Number 2660
• Preclinical Results:
  • ARR-002 targets both MUC16 and NaPi2b, which are highly expressed in ovarian and endometrial cancers but limited in normal tissue, making them ideal co-targets.
  • Novel tetravalent format allows simultaneous engagement and enhanced internalization compared to single-target ADCs.
  • Demonstrated:
    • Effective binding and enhanced internalization versus single-target controls.
    • Superior in vivo efficacy in the OVCAR-3 xenograft model compared to single-target ADCs.
    • Potential for a wider therapeutic window based on favorable tolerability in cynomolgus monkeys (reversible hematologic findings at higher maximum tolerated doses).
• Oral Mini-Symposium: Multi-epitope Targeting Tetravalent Antibody (MUTTA™) Platform for NextGen ADCs with Improved Therapeutic Window, April 21, 2026, 2:30–4:30 PM PT.

Strategic and Shareholder-Relevant Implications

• Firmonertinib is in pivotal global Phase 3 trials for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and EGFR PACC mutations (ALPACCA).
• Granted FDA Breakthrough Therapy and Orphan Drug Designations, highlighting potential for expedited development and regulatory review.
• ARR-002 (AV-P138-ADC) is the first-in-class, dual-target ADC, discovered in partnership with Aarvik Therapeutics and exclusively licensed to ArriVent for global development, expanding ArriVent’s oncology pipeline.
• Upcoming clinical milestones and top-line Phase 3 data releases for both assets are potentially significant price catalysts for shareholders.

About ArriVent BioPharma

ArriVent is dedicated to developing and commercializing differentiated medicines for cancer patients. The company leverages its deep drug development expertise to maximize the potential of its lead candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation ADCs, towards approval and commercialization.

Forward-Looking Statements

This article contains forward-looking statements reflecting ArriVent’s current expectations regarding clinical milestones, regulatory approvals, and the future potential of its product candidates. Actual results may differ due to risks and uncertainties in drug development, clinical trial outcomes, regulatory processes, and other factors. Investors are advised to review the company’s SEC filings for a discussion of these risks.

Contact: Joyce Allaire, LifeSci Advisors, LLC, [email protected]

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own due diligence and consult with a financial advisor before making investment decisions. The information provided is based on public disclosures as of the date of publication and may be subject to change.

View ArriVent BioPharma, Inc. Historical chart here